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Abstract
We developed a sensitive real-time polymerase chain reaction (QPCR) assay that allows us to track early lodging/
homing events in vivo. We used this technology to develop a metastasis assay of human prostate cancer (PCa)
growth in severe combined immunodeficient mice. For this purpose, marked human PCa cell lines were implanted
subcutaneously or in the prostate (orthotopically) of severe combined immunodeficient mice as models of primary
tumors. Mice were then sacrificed at various time points, and distant tissues were investigated for the presence of
metastatic cells. At 3 weeks, a number of tissues were recovered and evaluated by QPCR for the presence of meta-
static cells. The data demonstrate that several PCa cell lines are able to spread from the primary lesion and take up
residence in distant sites. If the primary tumors were resected at 3 weeks, in several cases, metastastic lesions were
identified over the course of 9 months. We propose that this new model may be particularly useful in exploring the
molecular events in early metastasis, identifying the metastatic niche, and studying issues pertaining to dormancy.
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Introduction
The metastatic spread of cancer cells is a dreaded complication of
malignant neoplasms. Metastasis is a multistep process in which ma-
lignant cells must initially escape from the primary tumor, invade the
surrounding tissues, and enter the vascular circulation [1]. If they are
able to survive in the blood stream, they must successfully arrest at a
secondary target site, cross the vascular barrier, and migrate into the
extravascular connective tissues. Subsequently, tumor cells may pro-
liferate to form a clinically relevant metastatic colony. Alternatively,
they may remain dormant, potentially never proliferating beyond a
microscopic focus of cells. The molecular bases of metastasis and,
particularly, dormancy are poorly understood.
Having a primary tumor as a source of cancer cells is clearly a
prerequisite for establishing metastases. It is also clear that primary
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tumors affect the host systemically, possibly priming distant tissues,
creating premetastatic niches that are conducive for tumor seeding
[2–4]. This may influence both the seeding rate and/or growth
of secondary tumors. It may also precondition selective sites for
the distinct metastatic patterns as described by Paget [5] in the origi-
nal seed-and-soil hypothesis. Yet, to study each of these possibilities
and, in particular, early metastatic events, a model system must be
in place, which recapitulates what is observed clinically. Unfortu-
nately, the number of experimental systems of spontaneous metasta-
sis using human prostate cancer (PCa) cell lines is limited. Moreover,
common systems used to explore metastasis bypass many of the early
steps in the process, particularly when the tumor cells are placed di-
rectly into the circulation.
To approach this problem, we developed a sensitive real-time po-
lymerase chain reaction (QPCR) assay that allows us to track early
lodging/homing events in vivo. We used this technology to develop
a metastasis assay of human PCa growth in severe combined immu-
nodeficient (SCID) mice. For this purpose, marked human PCa cell
lines were implanted subcutaneously (s.c.) or in the prostate (ortho-
topically) in SCID mice as models of primary tumors. Mice were
then sacrificed at various time points, and distant tissues were in-
vestigated for the presence of metastatic cells. At 3 weeks, a number
of tissues were recovered and evaluated by QPCR for the presence of
metastatic cells. These data demonstrate that several PCa cell lines are
able to spread from the primary lesion and take up residence in dis-
tant sites. If the primary tumors were resected at 3 weeks, in several
cases, metastastic lesions were identified over the course of 9 months.
We propose that this new model may be particularly useful in ex-
ploring the molecular events in early metastasis, identifying the
metastatic niche, and studying issues pertaining to dormancy. The
model is highly adaptable and amenable to experimental manipula-
tion, and as such, the model will clearly be useful to the scientific
community in identifying the molecular mechanisms of metastatic
PCa disease.
Materials and Methods
Cell Lines
LNCaP cells are androgen-responsive, nonmetastatic, and produce
mildly osteoblastic lesions when injected into the bone. C4-2B cells were
derived through serial passages of LNCaP cells in mice [6]. LNCaP
C4-2B cells, kindly provided by Dr. L. Chung (Emory University),
are androgen-independent, metastasize to bone, and form mixed osteo-
blastic/osteolytic lesions. PC-3 cells are androgen-independent, highly
metastatic, and produce very osteolytic lesions. PC-3 and LNCaP
C4-2B cells expressing a pLazarus retroviral construct containing lu-
ciferase were selected as described [7]. All cell lines were cultured in
RPMI 1640 containing 10% FBS and antibiotics and maintained at
37°C, 5% CO2, and 100% humidity.
Animal Manipulations
Male 5- to 7-week-old SCID mice (CB.17. SCID; Taconic, Ger-
mantown, NY), used as transplant recipients, were housed under con-
stant humidity and temperature, with 12-hour light/12-hour dark
cycles, and monitored daily. The animals were anesthetized by iso-
flurane inhalation. Each group consisted of a range of 8 to 10 animals.
On achieving the endpoints of the study, the animals were anesthe-
tized, and phlebotomy was performed by intracardiac puncture. The
animals were then sacrificed, and tissue samples were dissected free
from the surrounding tissues (the original scaffold, calvaria, brain,
tongue, mandible, heart, lung, kidney, adrenal gland, liver, periaortic
lymph nodes, prostate, tibia, humeri, femur, spleen, pelvis, spine, fat,
eye, and blood). Tissues were snap-frozen and stored at −80°C until
DNA extraction. DNA was extracted from the animals’ left organ/
tissue where applicable, with the following exceptions: the left lower
lobe of the lung and the left lobe of the liver. Extraction of DNA from
the entire brain, heart, and tongue was also performed.
Implantation of Scaffolds Containing PCa Cell Lines
Sterile collagen scaffolds (3 × 3 × 3 mm3, Gelfoam; Pharmacia &
Upjohn Co., New York, NY) were used for the transplantation of
human PCa cells. Immediately before transplantation, 2 × 105 PCa
cells were resuspended in 20 μl of RPMI 1640 containing 5% FBS
and antibiotics and were allowed to adsorb into the scaffolds. A sin-
gle mid dorsal incision was made for the implantation of the tumor-
bearing scaffolds and was closed with surgical clips. The animals were
monitored daily, and tumor volumes were calculated using the fol-
lowing formula: V = (the shortest diameter)2 × (the longest diameter)
at 21 days.
Tumor Initiation By Orthotopic Route
After anesthesia with ketamine (50 mg/kg) and xylazine (10 mg/kg),
a low midline incision was made in the lower abdomen. PCa cells (2 ×
105 in 20 μl of PBS) were injected into the right or left dorsolateral
lobe of the prostate, and the wound was closed with surgical clips [8].
Vertebral Body Transplant (Vossicle) Implantation
Lumbar vertebrae were isolated from the C57/Bl6 mice (Jackson
Laboratory, Bar Harbor, ME) within 4 days of birth. Soft tissues were
dissected, and the vertebrae were sectioned into single vertebral bod-
ies (vossicles) with a scalpel blade. Male 5- to 7-week-old SCID mice,
used as transplant recipients, were anesthetized with isoflurane inha-
lation. Two 1-cm incisions were made along the back of each mouse.
Pouches made on either side of the incision by blunt dissection were
implanted. Four vossicles were implanted in the dorsal region of each
mouse (n = 4). The surgical sites were closed with surgical clips.
Bioluminescence
Mice were injected intraperitoneally with luciferin (100 μl at
40 mg/ml in PBS) before imaging. This dose and route of administra-
tion have been shown to be optimal for rodent studies with a 10- to
20-minute post–luciferin injection [9]. Mice were anesthetized, and a
cryogenically cooled imaging system (IVIS Imaging System; Xenogen,
Mountain View, CA) was used for data acquisition [10]. Whole animal
imaging was used to monitor tumor growth. Signal intensities were
quantified as the sum of all detected photons (Figure W1).
Real-Time Polymerase Chain Reaction
DNA isolaton kits were used to prepare genomic DNA from the
designated tissues (DNeasy Blood and Tissue Kit (Cat. no. 69506);
Qiagen, Inc., Valencia, CA). DNA extraction was preformed directly
according to the Qiagen protocol. All sample concentrations were
standardized in each reaction to exclude false-positive results. Real-
time polymerase chain reactions were preformed using 15.0 μl of
TaqMan PCR Master Mix (Applied Biosystems, Foster City, CA) with
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100 nM of the Luc [TaqMan probes (F – 5′-CGG CTG GCA GAA
GCT ATG AA, R – 5′-TCG CTG CAC ACC ACG AT, TaqMan
probe – 5′-FAM-CTA TGG GCT GAA TAC AAA CC) or human
Alu TaqMan probes (F – 5′-CAT GGT GAA ACC CCG TCT CTA-
3′, R – 5′-GCC TCA GCC TCC CGA GTA G-3′, TaqMan probe –
5′-FAM-ATT AGC CGG GCG TGG TGG CG-TAMRA-3′); Ap-
plied Biosystems] [11] and 1 μg of the isolated tissue DNA in a total
volume of 30 μl. The thermal conditions were 50°C for 2 minutes,
95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds
and 60°C for 1 minute. The level of expression was detected as an
increase in fluorescence using a sequence detection system (ABI
PRISM 7700; Applied Biosystems). The DNA levels were expressed
as relative copies (% control) normalized against murine β-actin (Cat.
no. 4331182; Applied Biosystems), and a standard curve constructed
from serial dilutions of a purified Luc/Alu cDNA fragment was
cloned by classic PCR. Numerical data were determined against a
standard curve established using murine bone marrow containing
log-fold dilutions of human PCa cells. Positive and negative controls
include tissues obtained from non–PCa-injected mice or DNA de-
rived directly from PCa cells.
Parathyroid Hormone Injections
Mice were administered recombinant human parathyroid hor-
mone (1–34) (Bachem, Torrance, CA) or vehicle (0.9% saline) by
subcutaneous injection at 40 μg/kg per day for 3 weeks. Animals
were weighed weekly, and the dosage was adjusted accordingly [12].
Intravital Microscopy
Multiphoton imaging consisted of a modified confocal microscope
system (FluoView 300; Olympus, Center Valley, PA) coupled to a Mai
Tai Broadband, Mode-Locked Ti:sapphire Laser (Spectra-Physics,
Mountain View, CA) femtosecond-pulsed and tunable between 700
and 990 nm. A total of 2 × 105 PC-3 cells expressing green fluorescent
protein were implanted s.c. in SCID mice. At 3 weeks, 10 to 20 μl of
2 μM Qtracker 655-nm nontargeted quantum dots (Quantum Dot
Corporation, Hayward, CA) diluted in a total of 100 μl of PBS was
injected into the lateral tail vein to nonspecifically label vascular net-
work surrounding the resulting tumors. After 20 to 30 minutes, ani-
mals were anesthetized through intraperitoneal injection of ketamine/
xylazine. The skin was retracted laterally from the incision, and a
custom-made poly(dimethylsiloxane) viewing chamber was placed in
contact with the exposed skin. The chambers were filled with PBS
during the microscope observation lasting 30 to 90 minutes.
Immunohistochemistry
The formalin-fixed, decalcified, and paraffin-embedded tissues
were dewaxed and placed in a pressure cooker containing 0.01-M buff-
ered sodium citrate solution (pH 6.0), boiled, and chilled to room
temperature for antigen retrieval. Murine tissues were harvested and
fixed in 10% neutral-buffered formalin (Sigma, St. Louis, MO) over-
night. The long bones were decalcified in 10% EDTA, pH 7.5, for
14 days at 4°C. In addition, 7-μM paraffin-embedded slides were pre-
pared, stained with 20-μg/ml rabbit polyclonal to luciferase antibody
(Abcam Inc. Cambridge, MA) or an IgG (Sigma) in conjunction with
an HRP-AEC staining kit following the manufacturers’ protocols
(R&D Systems, Minneapolis, MN). Images were taken by a micro-
scope (Eclipse E800; Nikon, Melville, NY), with objective 40× NA
0.76, and a camera (RT Slider; Diagnostic Instruments, Sterling
Heights, MI) and were analyzed using a software (Image-Pro Plus ver-
sion 5.1.2.59; Media Cybernetics, Inc., Bethesda, MD).
Statistical Analysis
Numerical data are expressed as means ± SD. Statistical differences
between the means for the different groups were evaluated with
Instat 4.0 (GraphPad software, San Diego, CA) using one-way analy-
sis of variance (ANOVA) with the level of significance at P < .05.
Unless indicated, Kruskal-Wallis test and Dunn’s multiple compari-
sons tests were used with the level of significance set at P < .05.
Results
Dissemination Patterns of Human PCa Cell Lines
in SCID Mice
The prostate cancer field is critically lacking a metastasis assay in
which human tumor cells can be implanted in vivo and all the steps
of metastasis, including vascular invasion and egress, are achieved. In
recent studies, we developed an extremely sensitive QPCR assay that
allows us to track lodging/early homing events of hematopoietic stem
cells. We therefore evaluated whether this technology could be used
to develop a metastasis assay of human PCa growth in SCID animals.
For this purpose, 2 × 105 PC-3luciferase or LNCaP C4-2B cells were
initially implanted s.c. in sponges on the backs of SCID mice (e.g., a
primary tumor). At 3 weeks, a number of tissues were recovered and
evaluated for either human Alu sequences or luciferase by QPCR to
detect the presence of the human metastatic cells when the tumors
had reached an average of ∼209 ± 16.4 and ∼157 ± 12.3 mm2 for the
PC-3 and LNCaP C4-2B tumors, respectively. To establish cell
numbers, standard curves were generated using whole murine bone
marrow seeded with known numbers of human PCa cell lines (data
not presented).
As shown in Figure 1, s.c. implantation of PC-3 and LNCaP
C4-2B cells resulted in a significant number of shed or metastatic cells
in a variety of tissues. In animals that were not implanted with human
PCa, no Alu or luciferase signals were observed. LNCaP C4-2B cell
levels were generally higher than PC-3 levels in the soft tissues eval-
uated, although no consistent pattern was noted for the distribution.
In osseous tissues, PC-3 cell levels were highest in the calvaria, femur,
and humeri, whereas LNCaP C4-2B levels were higher in the spine
and tibia (Figure 1).
Disseminated Human PCa Cells Are Able to Form Tumors
The preceding results suggest that human PCa cells are able leave
the primary tumor and disseminate to distant organs. As an alternative
explanation, genetic material shed from the human cells was identified
by PCR in the murine tissues. As an initial attempt to distinguish be-
tween these possibilities, two separate studies were performed. In the
first, a multiphoton imaging system was used to examine in real-time
the localization of PCa cells and stromal components in tissues up to
1 mm in depth. PC-3 cells expressing green fluorescent protein were
grown s.c. in SCID mice. The animals were then injected with non-
targeted quantum dot 605-nm solution to label the blood vessels. To
determine if the human PCa cells were able to egress from the primary
tumor, a ∼0.5-cm incision was made in the skin on one side of the
tumor in a crescent shape, and the tumor-bearing skin flap was exter-
nalized and viewed. Figure 2A demonstrates a fairly compact tumor
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Figure 1. Development of a metastasis assay for human PCa. Luciferase-labeled PC-3 or LNCaP C4-2B cells (2 × 105 cells) were
implanted s.c. in sponges on the backs of SCID mice (n = 10) as a primary tumor model. At 3 weeks, the animals were sacrificed,
and tissues were removed. QPCR was used to detect human Alu sequences (shown) or luciferase (not shown) derived from the human
PCa cells. Pilot studies, not shown, demonstrated a ∼1:1 correlation between QPCR tracking of human Alu and luciferase sequences.
Resultant numbers were generated against a standard curve established by mixing known numbers of PC-3 or C4-2B cells in mouse
marrow. Further normalization was performed for differences in mouse tissue density using murine β-actin primers. Human Alu was not
identified in animals not receiving a s.c. tumor (No Tumor). *Significance difference of PC-3 versus C4-2-B (P< .05). Data show that shed
or metastatic PCa cells can be identified in a number of tissues derived from s.c. tumors.
Figure 2. Multiphoton imaging of initial tumor dissemination. A multiphoton imaging system was used to examine in real-time the
localization of PCa cells and stromal components in tissues. PC-3 cells expressing green fluorescent protein were grown s.c. in SCID
mice. At 3 weeks, the animals were injected with a nontargeted quantum dot (605 nm) to label the blood vessels (Red). Thirty minutes
later, tumor-bearing skin flaps were elevated and viewed. (A) Compact tumor with a few PC-3 cells outside of the tumor border (TB)
(drawn in yellow). Arrows indicate individual GFP expressing PC-3 cells. (B) A number of tumor cells ∼200 μm beyond the tumor
periphery. (C and D) A gradient of metastatic cells extending into the surrounding tissues.
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with a few tumor cells outside of the tumor border. Figure 2B demon-
strates a few tumor cells ∼200 μm beyond the tumor peripheri, and
Figure 2, C and D, demonstrates a gradient of metastatic cells extend-
ing into the surrounding tissues.
A second method to distinguish between shed genetic material or
cells was to determine if shed cells from the s.c. tumors are capable of
generating real metastatic lesions. We reasoned that this would be the
case if the animals were able to survive long enough for metastatic
lesions to appear. To test this concept, primary s.c. PC-3luc tumors
were established in SCID mice (n = 10). Other animals were im-
planted with scaffolds only. After 3 weeks, the 1° tumors were re-
sected, and the animals imaged to ensure 1° tumor was removed
(Figure 3A). The animals were followed for up to 9 months. Two
animals became cachectic at 3 months and were sacrificed. On gross
dissection, one of these animals had a large abdominal mass (Fig-
ure 3B) and had disseminated tumors in the lymph nodes, liver
(Figure 3C ), parotid gland, and lungs. The other animal had a large
shoulder mass and liver metastases (Figure 3, D–G). Three additional
animals were sacrificed at 6 months, and each had evidence of tumor
in multiple organs. One of the three remaining animals was sacrificed
at 9 months because the total luciferase signals of the remaining ani-
mals began to rise (Figure 3A). In one case, a single bone metasta-
sis was noted (Figure 3, H–J ). QPCR demonstrated that tumor cells
were present in the remaining two animals after 9 months (not
shown). Sham-operated animals did not demonstrate any of these
symptoms. These data demonstrate that the disseminated tumor cells
from a primary subcutaneous tumor are able to generate metastases
as 6 of 8 animals developed tumors.
Tumor Shedding Modulated By Parathyroid Hormone
and to Exogenous Tissues
Two further studies were performed to determine the usefulness of
our experimental model. In the first set of studies, s.c. tumors were
established in SCID mice using PC-3 cells. One group of animals
was treated daily with human parathyroid hormone (PTH) begin-
ning 24 hours after tumor implantation for the duration of the study;
another group was treated with vehicle only. The levels of PC-3 re-
covered from a number of tissues were evaluated at 3 weeks. Focusing
on the bones, PTH treatments produced variable levels of tumor cells
in each of the bone tissues (Figure 4). Most notably, PTH reduced
the number of PC-3 cells found in the calvaria and pelvis, while it
increased the number of cells in the mandible, tibia, and spine. There
were no significant differences noted in the femurs.
Our group has developed an osteogenic assay in which neonatal
skeletal elements form bone in vivo (e.g., vertebral body or vossicles),
creating an ectopic bone marrow environment where bone niches are
Figure 3. Cells derived from a s.c. tumor generate disseminated tumors over time. Luciferase labeled PC-3− (2 × 105 cells) were im-
planted s.c. in sponges on the backs of SCID mice (n = 10) as a model of a primary tumor. At 3 weeks, the animals were anesthetized
and the tumors resected. (A) Total luciferase signals of animals over the course of 9 months. (B) Abdominal mass (arrows) and (C)
liver metastasis (arrows) identified in cachectic animals at 3 months following s.c. tumor implantation and removal. (D and E) Negative
and positive (red) immunostaining for pan human cytokeratin (human heart and PCa bone met). Detection of PC-3 cells in a shoulder
tumor mass (F) and liver metastasis detected at 3 months (G). Bioluminescent imaging of positive (left arrow) and negative bone (right
arrow) metastatic lesions (H) and negative (I) and positive (J) immunostaining for luciferase of the bones shown in H. Scale bars, 100 μm
unless indicated.
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generated and can be studied [13,14]. We therefore used the metas-
tasis model in conjunction with vossicles to explore if PCa metasta-
sizes to vossicles. Here, mid dorsal s.c. tumors were established using
PC-3 cells in SCID mice. At the same time, a total of four vossicles
from C57/Bl6 neonates were implanted bilaterally in the right and
left shoulder and pelvic regions. At harvest, QPCR was performed.
All of the vossicles had tumor cells comparable (or greater) to the
levels of tumor cells in the humeri or spine (Figure 5).
Comparisons of Metastasis Generated By Orthotopic
Versus s.c. Tumors
Recently, debate has centered on the utility of s.c. tumor models
versus orthotopic models [15–20]. We therefore directly compared
the level of tumor dissemination generated by orthotopic versus s.c.
tumors in our model. Here, 2 × 105 PC-3 cells were either implanted
s.c. or directly into the right or left lobe of the dorsolateral pros-
tate. After 3 weeks, the PC-3 cells were identified by QPCR in many
tissues, including the bone, for both delivery methods (Figure 6).
However, it was clear that for soft-tissue metastases, an orthotopic
model was superior. For metastasis in bones, the orthotopic model
was also superior, although statistical differences exist.
Discussion
Using an extremely sensitive QPCR assay, we were able to demon-
strate that both LNCaP C4-2B and PC-3 cell lines disseminate from
a primary s.c. tumor site and populate many distant organs, recapitu-
lating many of the early events necessary for metastasis. This is im-
portant for the field as it is critically lacking a metastasis assay in
which human tumor cells can be implanted in vivo and all the steps
of metastasis, including vascular invasion and egress, are achieved.
Our data demonstrate that primary tumors established by LNCaP
C4-2B and PC-3 cells shed cells to soft tissues and bone. One sur-
prising aspect of our findings was the observation that different levels
of tumor dissemination were noted in a variety of tissues despite the
fact that essentially equal levels of LNCaP C4-2B and PC-3 cells
were detected in the blood. One possible explanation for these ob-
servations may be due to inherent differences in the egress rates of
the cells into peripheral tissues once they have reached the vascular
compartment. At the present time, little information is available to
distinguish between egress rates of tumor cells. Vascular egress con-
stitutes a combination of both vascular adhesion and transendothelial
migration. A second scenario may be that equal numbers of cells are
seeded into the tissues but that proliferation rates in peripheral tissues
vary. Here, combinations of local growth factors and inherent auton-
omous proliferation differences may have led to different levels of
tumor cells in the tissues. Further experimentation will be required
to delineate between these possibilities.
Recent debate has centered on the utility of s.c. tumor models ver-
sus orthotopic models [15–20]. We also share these concerns, and we
therefore determined if metastatic cells can be generated from an
orthotopic route of tumor initiation. We directly compared ortho-
topic versus s.c. metastasis in our model and determined that the ge-
netic signature of PC-3 cells was identified by QPCR in many tissues,
including bone, for both delivery methods. However, it was clear that
the orthotopic model was superior for soft tissue metastases. For skele-
tal metastases, the orthotopic model was superior for the cells shed to
the mandible, spine, and tibia. The s.c. method of tumor initiation
was superior for cells shed to the calvaria, femur, humeri, and pelvis.Figure 3. (continued)
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The reason for the differences in seeding to the bones is not clear. A
purely vascular rationale relating to blood flow seems unlikely. One
possibility is that tumor cells generated at the different primary sites
select for cellular populations with different metastatic preference.
If this latter prospect is true, it will require further exploration to test
this possibility.
As stated in the introduction, a necessary prerequisite for metasta-
sis is having a primary tumor. It is also clear that soluble factors re-
leased from a primary lesion are likely to activate distant sites making
it more feasible for metastasis to occur. One mechanism that had
previously been demonstrated is the activation of vascular endothe-
lial cells to express de novo vascular adhesion molecule 1 (VCAM-1)
in response to soluble tumor-derived tumor necrosis factor. This
facilitates myeloma and osteosarcoma spread through vascular adhe-
sion molecule 1/very late antigen 4 interactions. More recently, it has
been demonstrated that the presence of a tumor activates the bone
marrow to release endothelial progenitor cells that seed distant organs
to establish a premetastatic niche [2–4]. This may influence both the
Figure 4.Modulation of tumor dissemination by daily administration of PTH. Subcutaneous tumors were established in SCID mice using
PC-3 cells. Mice were injected s.c. with recombinant human PTH fragments 1 to 34 (Bachem) at 40 μg/kg body weight per day or with
the vehicle (acidified saline), 7 days/week for 3 weeks (n = 8 per group). Body weight was measured weekly, and dose was adjusted
accordingly. The levels of PC-3 recovered from a number of tissues were evaluated at 3 weeks. *P < .05 from vehicle.
Figure 5. Homing of PCa to vossicle tissues. Lumbar vertebrae (vossicles or Vos.) were isolated from neonatal C57/Bl6 mice within
4 days of birth. Vos. transplants were implanted into s.c. pouches established in the right and left shoulder (RS, LS) or pelvic (RP,
LP) pouches into male 5- to 7-week-old SCID mice (n = 8). At the same time, s.c. PC-3 tumors were established in sponges in the
mid dorsal region. At 3 weeks, the animals were sacrificed, and tissues were removed. QPCR was used to detect human Alu sequences
derived from the human PCa cells. Resultant numbers were generated against a standard curve established by mixing known numbers
of PC-3 in mouse marrow using murine β-actin primers. Controls included the femur of sham-operated animals (No Tumor). *Significant
differences from the levels of PC-3 in the spleen (P < .05). Data show that shed or metastatic PCa cells derived from an s.c. tumor can
be identified in the vossicles.
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seeding rate and/or growth of secondary tumors. It may also precon-
dition selective sites for the distinct metastatic patterns as described
by Paget [5] in the original seed-and-soil hypothesis.
A particular interest we have in developing this model is its poten-
tial flexibility. For example, with PTH injected daily s.c., the ob-
served metastatic patterns were altered. PTH has many known
physiologic functions, and PTH-related protein (PTHrP) is pro-
duced by virtually all tumor types that metastasize to bone. PTH
and PTHrP mediate their major known actions in bone by means
of binding to the PTH-1 receptor on osteoblastic cells. Both proteins
regulate osteoblast proliferation and differentiation in a time- and
dose-dependent manor. Bone remodeling has also been implicated
in the localization of tumors to bone. PTH and PTHrP are known
to increase bone turnover by enhancing the expression of the receptor
activator of NF-κB ligand in osteoblasts, which drives and activates
osteoclastic bone resorption. In addition, an emerging role for PTH
in the regulation of hematopoiesis has recently been described by ex-
panding the size of the hematopoietic stem cell niche [21–24]. Our
data demonstrate that daily PTH injections altered the observed meta-
stastic patterns. One possible mechanism that would account for
this finding is the observation that stromal-derived factor 1 (SDF-1)
production by osteoblasts is regulated by PTH in vitro [23]. When
animals were treated with an anabolic regime of PTH for 21 days,
significant increases in SDF-1 mRNA expression were observed near
the growth plate and epiphysis regions of the long bones [23]. Yet, in
serum, immunodetectable SDF-1 levels were significantly reduced
(24%) in the PTH-treated animals (vehicle, 408 ± 25 pg/ml SDF-1
vs PTH, 308 ± 20 pg/ml SDF-1). Additionally, differential activa-
tion of osteoclastic activity can contribute to this possibility. Clearly,
further study will be needed to correlate the changes in metastatic
cells to SDF-1 levels in each bone. However, these data suggest a
possible mechanism for localizing stem cells into a developing mar-
row where increased expression of SDF-1 in the local marrow envi-
ronment along with decreased SDF-1 in the serum may create a
homing gradient. Yet, the design of our study did not permit us to
determine whether these effects were due to the direct effects of PTH
on the primary tumor, metastastic spread, or changes in the bone
microenvironment.
Another example of the flexibility that this model affords is that we
have demonstrated that human PCa cells are able to metastasize to
vossicles which could be generated using transgenic tissues [13,14].
This provides a platform to test the effects of different microenviron-
mental factors on metastasis that would not be possible without first
crossing the transgenic animals onto an immunocompromised back-
ground. Finally, by resecting the primary tumor, the majority of the
mice in our study survived longer than 3 months. This strategy, in
which animals with disseminated cells survive for relatively long pe-
riods of time, may provide opportunities to study issues related to the
metastasis-targeted treatments and the induction of tumor dormancy.
Paget [5] first proposed a seed and soil metaphor to explain the
marked affinity of cancer cells for different tissues stating that, “when
a plant goes to seed, its seeds are carried in all directions; but they can
only grow if they fall on congenial soil.” It is likely that the majority
of the cells identified by our PCR methods do not truly represent
cells capable of proliferation at distant sites. As such, the model more
closely recapitulates the human experience, where a large and perhaps
Figure 6. Comparison of metastasis from orthotopic versus s.c. sites. Luciferase-labeled PC-3 cells (2 × 105) were implanted s.c. in
sponges or orthotopically in SCID mice (n = 10) as a model of a primary tumor. At 3 weeks, the animals were sacrificed, and QPCR
was used to detect human Alu sequences (shown) or luciferase (not shown) derived from the human PCa cells. Human Alu sequences
were not identified in animals that did not receive a s.c. tumor (No Tumor). *Orthotopic superior to s.c. and +s.c. superior to orthotopic
(P < .05). Data demonstrate that both s.c. and orthotopic routes of establishing a primary tumor results in metastatic seeding of a
number of tissues.
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constant flux of shed tumor cells occurs. Yet clinically, relatively few
overt metastatic lesions are observed. It is also likely that cells shed
from either the s.c. or orthotopic sites engage the local microenvi-
ronments or tissue niches to remain quiescent differently than intra-
vascularly injected cells do. As such, this model may therefore be
particularly valuable for identifying mechanisms that regulate quies-
cence and for identifying prostate cancer stem cells.
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Figure W1. Comparison of the sensitivity of QPCR versus bioluminescent imaging (BLI) of PCa cells. Representative standard curves
were generated for PC-3luciferase cells. For standard curve generation, log-fold dilution of PC-3luciferase cells (0–1 × 106) mixed with 106
nucleated murine bone marrow cells was performed. (A) DNA was extracted, and QPCR was used to determine human Alu, luciferase,
and murine β-actin. PC-3luciferase cell number was plotted against cycle number where Alu detection is slightly more sensitive than
luciferase detection. (B) BLI of log-fold dilution of PC-3luciferase cells (0–1 × 106) mixed with 106 nucleated murine bone marrow cells.
Data demonstrate that QPCR is able to detect ∼100 cells, whereas the detection limit for the BLI is ∼1000 cells.
